ProCE Banner Activity

How I Apply New Clinical Developments to the Management of Metastatic Breast Cancer

Clinical Thought

Komal Jhaveri, MD, FACP, shares her insights on applying new clinical developments in managing patients with metastatic breast cancer in a rapidly evolving treatment landscape, taking into consideration recent or impending FDA approvals and individualizing patient care

Released: July 25, 2023

Share

Faculty

Komal Jhaveri

Komal Jhaveri, MD, FACP

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Daiichi Sankyo

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Disclosure

Primary Author

Komal Jhaveri, MD, FACP

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Gilead, Jounce Therapeutics, Lilly/Loxo Oncology, Menarini/stemline, Novartis, Olema Pharmaceuticals, Pfizer, Seattle Genetics, Sun Pharma Advanced Research Company Ltd, Taiho Oncology; researcher (paid to institution): AstraZeneca, Context Therapeutics, Debio Pharmaceuticals, Genentech/Roche, Gilead, Lilly/Loxo Oncology, Merck, Novartis, Pfizer, PUMA Biotechnology, Zymeworks.